Lung Cancer

Dr. Edward Garon discusses the use of PD-1 and PD-L1 inhibitors in patients with lung cancer.
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.
Dr. Edward Garon speaks about how differences in patient populations with lung cancer can make it difficult to interpret and act on data.
Dr. Edward Garon shares an anecdote about an interesting NSCLC case from his practice.
Dr. Edward Garon explains how he discusses immunotherapies with patients.
Dr. Edward Garon describes how staff at his practice interacts with patients.
Dr. Edward Garon believes it's important to recognize that agents without efficacy are not beneficial to the patient despite low toxicity.
Toxicities related to immunotherapies approved for the treatment of patients with non–small-cell lung cancer (NSCLC) are uncommon but can be life-threatening.
It is now widely known that light cigarettes are no safer than regular cigarettes and were only marketed in an attempt to undermine smokers’ wishes to quit smoking. According to Charlotta Pisinger, PhD, MPH, the tobacco industry is now using the same tactic with electronic cigarettes (e-cigarettes).
Targeted agents and immunotherapy are displacing chemotherapy in certain subgroups of the treatment of lung cancer, but chemotherapy remains a key therapeutic pillar in the daily management of patients with this disease, according to Jean-Charles Soria, MD, PhD, Head of the Drug Development Department, Gustave Roussy, Villejuif, France.
Page 4 of 8
Results 31 - 40 of 78

©2019 Green Hill Healthcare Communications, LLC, an affiliate of The Lynx Group. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512